PDCD1 and non-small cell lung carcinoma: Nivolumab and pembrolizumab (monoclonal antibodies against PD-1) are approved for the therapy of cutaneous melanoma, non-small cell lung cancer (NSCLC), kidney cancer, bladder cancer, head and neck cancers, and Hodgkin lymphoma.